Search results for "leukemia"

showing 10 items of 976 documents

Impact of combinations of single-nucleotide polymorphisms of anthracycline transporter genes upon the efficacy and toxicity of induction chemotherapy…

2020

Anthracycline uptake could be affected by influx and efflux transporters in acute myeloid leukemia (AML). Combinations of single-nucleotide polymorphisms (SNPs) of wild-type genotype of influx transporters (SLC22A16, SLCO1B1) and homozygous variant genotypes of ABC polymorphisms (ABCB1, ABCC1, ABCC2, ABCG2) were evaluated in 225 adult de novo AML patients. No differences in complete remission were reported, but higher induction death was observed with combinations of SLCO1B1 rs4149056 and ABCB1 (triple variant haplotype, rs1128503), previously associated with ABCB1 and SLCO1B1 SNPs. Several combinations of SLCO1B1 and SLC22A16 with ABCB1 SNPs were associated with higher toxicities, includin…

AdultCancer ResearchGenotypeAnthracyclineSingle-nucleotide polymorphismPolymorphism Single Nucleotide03 medical and health sciences0302 clinical medicineMucositisHumansMedicineIdarubicinAnthracyclinesProspective StudiesbiologyLiver-Specific Organic Anion Transporter 1business.industryHaplotypeInduction chemotherapyMyeloid leukemiaInduction ChemotherapyHematologymedicine.diseaseMultidrug Resistance-Associated Protein 2Leukemia Myeloid AcuteOncology030220 oncology & carcinogenesisbiology.proteinCancer researchATP-Binding Cassette TransportersbusinessSLCO1B1030215 immunologymedicine.drugLeukemia & Lymphoma
researchProduct

A Phase I Study of Intravenous LBH589, a Novel Cinnamic Hydroxamic Acid Analogue Histone Deacetylase Inhibitor, in Patients with Refractory Hematolog…

2006

Abstract Purpose: LBH589 is a novel histone deacetylase inhibitor that inhibits proliferation and induces apoptosis in tumor cell lines. In this phase I study, LBH589 was administered i.v. as a 30-minute infusion on days 1 to 7 of a 21-day cycle. Experimental Design: Fifteen patients (median age, 63 years; range, 42-87 years) with acute myeloid leukemia (13 patients), acute lymphocytic leukemia (1 patient), or myelodysplastic syndrome (1 patient) were treated with LBH589 at the following dose levels (mg/m2): 4.8 (3 patients), 7.2 (3 patients), 9.0 (1 patient), 11.5 (3 patient), and 14.0 (5 patients). The levels of histone acetylation were measured using quantitative flow cytometry and plasm…

AdultCancer ResearchIndolesMaximum Tolerated Dosemedicine.drug_classApoptosisPharmacologyHydroxamic AcidsDrug Administration ScheduleHistonesStructure-Activity Relationshipchemistry.chemical_compoundPredictive Value of TestsPanobinostatAcute lymphocytic leukemiaPanobinostatBiomarkers TumormedicineHumansEnzyme InhibitorsAgedCell ProliferationAged 80 and overDose-Response Relationship Drugbusiness.industryHistone deacetylase inhibitorArea under the curveQTcF ProlongationMyeloid leukemiaMiddle AgedPrecursor Cell Lymphoblastic Leukemia-Lymphomamedicine.diseaseHypokalemiaHistone Deacetylase InhibitorsLeukemiaTreatment OutcomeOncologychemistryCinnamatesLeukemia MyeloidMyelodysplastic SyndromesAcute DiseaseInjections IntravenousImmunologymedicine.symptombusinessFollow-Up StudiesClinical Cancer Research
researchProduct

Impaired muscle strength in female adolescents and young adults surviving leukemia in childhood

1993

Background. With the improving cure rate in childhood malignancies, increasing interest has been focused on long-term survivors. To evaluate late sequelae of childhood leukemia, the muscle strength of 43 young female survivors was investigated and compared with that of 69 healthy age-matched women. The patients had been off therapy for 1 to 19 years. Methods. The anthropometric characteristics measured were height and weight, and body mass index was calculated. The maximal isometric strengths for elbow flexion, knee extension, and hand grip were measured on a special dynamometer chair. Dynamic muscular endurance was measured by pushup and situp tests. Results. The mean height of the patient…

AdultCancer Researchmedicine.medical_specialtyAdolescentChildhood leukemiaIsometric exerciseQuality of lifeReference ValuesIsometric ContractionmedicineHumansYoung adult2. Zero hungerLeukemiabusiness.industryMusclesBody WeightAnthropometrymedicine.diseaseBody HeightOncologyEl NiñoAcute DiseasePhysical therapyFemaleCranial Irradiationmedicine.symptombusinessBody mass indexWhole-Body IrradiationFollow-Up StudiesMuscle contractionCancer
researchProduct

Cancer consequences of the Chernobyl accident in Europe outside the former USSR: A review

1996

The accident which occurred during the night of April 25-26, 1986 in reactor 4 of the Chernobyl nuclear power plant in the Ukraine released considerable amounts of radioactive substances into the environment. Outside the former USSR, the highest levels of contamination were recorded in Bulgaria, Austria, Greece and Romania, followed by other countries of Central, Southeast and Northern Europe. Studies of the health consequences of the accident have been carried out in these countries, as well as in other countries in Europe. This report presents the results of a critical review of cancer studies of the exposed population in Europe, carried out on the occasion of the 10th anniversary of the …

AdultCancer Researchmedicine.medical_specialtyNeoplasms Radiation-InducedAdolescentEnvironmental protectionNeoplasmsmedicineHumansThyroid NeoplasmsChildSocioeconomicsAccident (philosophy)AgedLeukemia Radiation-InducedHealth consequencesIncidencePublic healthInfant NewbornInfantDose-Response Relationship RadiationEnvironmental exposureMiddle Agedcancer ; thyroid ; leukaemia ; nuclear accident ; ChernobylEuropeGeographyOncologyChild PreschoolRadioactive Hazard ReleaseUkrainePower PlantsInternational Journal of Cancer
researchProduct

Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients.

2007

Myeloid sarcoma ( MS) is a rare neoplasm whose knowledge is largely based on case reports and/or technically dated contributions. Ninety-two MSs in adulthood with clinical data available were evaluated both morphologically and immunohistochemically. Seventy-four cases were also studied by fluorescent in situ hybridization on tissue sections and/or conventional karyotyping on bone marrow or peripheral blood. Histologically, 50% of the tumors were of the blastic type, 43.5% either monoblastic or myelomonocytic and 6.5% corresponded to different histotypes. CD68/KP1 was the most commonly expressed marker (100%), followed by myeloperoxidase (83.6%), CD117 (80.4%), CD99 (54.3%), CD68/PG-M1 (51%)…

AdultGenetic MarkersMaleCancer ResearchPathologymedicine.medical_specialtyAdolescentLymphomaCD34BiologyTrisomy 8Translocation Geneticcytogeneticsmyeloid sarcoma; chloroma; FISH; cytogenetics; immunohistochemistry; prognosisFISHAntigens CDmyeloid sarcomamedicineMyeloid sarcomaHumansIn Situ Hybridization FluorescenceAgedAged 80 and overChromosome Aberrationsmedicine.diagnostic_testCytogeneticschloromaSarcomaHematologyMiddle Agedmedicine.diseaseTransplantationLeukemiaPhenotypeOncologyLeukemia MyeloidimmunohistochemistryFemaleprognosisSarcomaalpha interferonCD30 antigenCD34 antigenFluorescence in situ hybridization
researchProduct

Genesis of variant Philadelphia chromosome translocations in chronic myelocytic leukemia.

2003

The Philadelphia (Ph) chromosome is found in more than 90% of chronic myelocytic leukemia (CML) patients. In most cases, it results from the reciprocal t(9;22)(q34;q11), with the ABL proto-oncogene from 9q34 fused to the breakpoint cluster region (BCR) locus on 22q11. In 5%-10% of patients with CML, the Ph chromosome originates from variant translocations, involving various breakpoints in addition to 9q34 and 22q11. In our investigation, three CML cases with complex Ph translocations have been analyzed by G-banding and fluorescence in situ hybridization (FISH). FISH with breakpoint-spanning probes for the BCR and ABL genes revealed information about the genesis of complex Ph translocations.…

AdultGenetic MarkersMaleCancer Researchmedicine.medical_specialtyChromosomes Human Pair 22Chromosomal translocationLocus (genetics)BiologyPhiladelphia chromosomeProto-Oncogene MasTranslocation Genetichemic and lymphatic diseasesLeukemia Myelogenous Chronic BCR-ABL PositiveGeneticsmedicineHumansPhiladelphia ChromosomeMolecular BiologyIn Situ Hybridization FluorescenceGeneticsABLmedicine.diagnostic_testChromosomes Human Pair 11BreakpointCytogeneticsbreakpoint cluster regionGenetic VariationMiddle Agedmedicine.diseaseChromosome BandingKaryotypingFemaleChromosomes Human Pair 9Fluorescence in situ hybridizationCancer genetics and cytogenetics
researchProduct

The new HFA/ICOS risk assessment tool to identify patients with chronic myeloid leukaemia at high risk of cardiotoxicity

2022

AimsTyrosine kinase inhibitors (TKIs) used to treat chronic myeloid leukaemia (CML) can cause cardiovascular adverseevents. So far, the Systematic Coronary Risk Evaluation (SCORE) charts of the European Society of Cardiology (ESC) have beenused to identify cancer patients at increased cardiovascular risk. The primary aim of our study was to evaluate the usefulnessof the new cardiovascular risk assessment model proposed by the Cardio-Oncology Study Group of the Heart Failure Associ-ation (HFA) of the ESC in collaboration with the International Cardio-Oncology Society (ICOS) to stratify the cardiovascular riskin CML patients, compared with SCORE risk charts. The secondary aim was to establish…

AdultHeart FailureMaleAspirinMiddle AgedRisk AssessmentCardio-oncology Cardiovascular prevention Chronic myeloid leukaemia Nilotinib Ponatinib Cardiovascular toxicityCardiotoxicityInducible T-Cell Co-Stimulator ProteinLeukemia Myelogenous Chronic BCR-ABL PositiveChronic DiseaseHumansFemaleCardiology and Cardiovascular MedicineAgedRetrospective StudiesESC Heart Failure
researchProduct

Incidence of lineage promiscuity in acute myeloblastic leukemia: Diagnostic implications of immunoglobulin and T-cell receptor gene rearrangement ana…

1988

Abstract Sixty-nine blood or bone marrow samples from both children and adults with acute myeloblastic leukemia (AML) were investigated to elucidate the frequency of immunoglobulin (IG) and T-cell receptor (TCR)-gene rearrangements. Non-germline configuration for the IG heavy chain (h) gene was detected in the specimens of nine patients of various subtypes according to the French-American-British classification (FAB), including FAB M1, M2, M4 and M5. Rearrangement of the IG kappa chain (k) gene was present in one of these cases which simultaneously revealed a rearranged TCR-beta (b) chain gene. In another two AML samples we found TCR-b gene rearrangements, in one case in combination with an…

AdultImmunoglobulin geneCancer ResearchAcute myeloblastic leukemiaCD19medicineHumansGene Rearrangement beta-Chain T-Cell Antigen ReceptorChildGenes ImmunoglobulinbiologyAntibodies MonoclonalCell DifferentiationHematologyGene rearrangementmedicine.diseaseMolecular biologyLeukemia Myeloid AcuteLeukemiaPhenotypeOncologyTerminal deoxynucleotidyl transferaseT-Cell Receptor Genebiology.proteinAntibodyImmunoglobulin Heavy ChainsLeukemia Research
researchProduct

Selective Depletion of Alloreactive T Lymphocytes Using Patient-Derived Nonhematopoietic Stimulator Cells in Allograft Engineering

2008

Background. Selective depletion of alloreactive T cells in vitro results in efficient graft-versus-host disease prophylaxis in allogeneic hematopoietic stem-cell transplantation, but it is accompanied by increased recurrence of leukemia. To spare donor T-cell-mediated graft-versus-leukemia immunity against hematopoiesis-restricted minor histocompatibility (minor-H) antigens, we explored the use of patient-derived nonhematopoietic antigen-presenting cells (APC) as allogeneic stimulators for selective allodepletion in leukemia-reactive donor T-cell lines. Methods. Primary keratinocytes, dermal fibroblasts, and bone marrow fibroblasts were generated from skin biopsies and diagnostic bone marro…

AdultKeratinocytesT-LymphocytesLymphocyteGraft vs Host DiseaseHuman leukocyte antigenLymphocyte DepletionInterferon-gammaTumor Necrosis Factor Receptor Superfamily Member 9AntigenAntigens CDmedicineHumansTransplantation HomologousSkinB-LymphocytesHLA-D AntigensTransplantationCD40Tissue EngineeringbiologyHistocompatibility Antigens Class IHematopoietic Stem Cell TransplantationDermisT lymphocyteFibroblastsmedicine.diseaseLeukemiamedicine.anatomical_structureEpidermal CellsImmunologybiology.proteinBone marrowEpidermisCD8Transplantation
researchProduct

All-trans retinoic acid as adjunct to intensive treatment in younger adult patients with acute myeloid leukemia: results of the randomized AMLSG 07-0…

2016

The aim of this clinical trial was to evaluate the impact of all-trans retinoic acid (ATRA) in combination with chemotherapy and to assess the NPM1 status as biomarker for ATRA therapy in younger adult patients (18–60 years) with acute myeloid leukemia (AML). Patients were randomized for intensive chemotherapy with or without open-label ATRA (45 mg/m2, days 6–8; 15 mg/m2, days 9–21). Two cycles of induction therapy were followed by risk-adapted consolidation with high-dose cytarabine or allogeneic hematopoietic cell transplantation. Due to the open label character of the study, analysis was performed on an intention-to-treat (ITT) and a per-protocol (PP) basis. One thousand one hundred pati…

AdultMale0301 basic medicineAcute promyelocytic leukemiaOncologymedicine.medical_specialtyNPM1Adolescentmedicine.medical_treatmentTretinoinYoung Adult03 medical and health sciences0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansddc:610ChemotherapyAcute myeloid leukemiaHematologyAll-trans retinoic acidbusiness.industryMyeloid leukemiaInduction ChemotherapyHematologyGeneral MedicineMiddle Agedmedicine.disease3. Good healthSurgerySurvival RateTransplantationClinical trialLeukemia Myeloid AcuteTreatment Outcome030104 developmental biologyNucleophosmin-1Acute myeloid leukemia; All-trans retinoic acid; Nucleophosmin-1030220 oncology & carcinogenesisCytarabineFemaleOriginal ArticlebusinessNucleophosminFollow-Up Studiesmedicine.drug
researchProduct